Germany · Delayed Price · Currency is EUR Enanta Pharmaceuticals Company Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications.
The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.
It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir.
The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 1995 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 120 |
| CEO | Jay Luly |
Contact Details
Address: 4 Kingsbury Avenue Watertown, Delaware 02472 United States | |
| Phone | 617 607 0800 |
| Website | enanta.com |
Stock Details
| Ticker Symbol | 9EP |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jay Luly | Chief Executive Officer |
| Harry Trout | Chief Financial Officer |
| Jennifer Viera | Head of Investor Relations |